ZLAB Zai Lab Ltd Insider Trading

Director Richard Gaynor buys 1,736 shares of ZLAB at $19.05 under pre-arranged 10b5-1 plan; stock -53.7% from 52-week high.

Richard Gaynor purchased 1,736 shares at $19.05 on 2026-07-01 as part of a 10b5-1 trading plan adopted on 2025-12-16, making this a scheduled transaction rather than a discretionary trade. ZLAB is trading at $19.08, approximately -53.7% from its 52-week high of $41.20, though the stock has gained 14.8% over the prior 30 days. The company remains unprofitable with a net loss of $-51.0M against revenue of $99.6M in the latest quarter, despite annual revenue growth of 15.3%. Gaynor's prior purchase at this ticker on 2026-03-17 showed similar post-purchase price action: +24.3% over 30 days followed by -6.2% over 90 days, which mirrors the recent 30-day gain and negative longer-term trajectory now visible in the current price context.

CEO/then-Chair Du Ying sold 100,000 ZLAB shares for $1,986,875 via scheduled 10b5-1 plan; stock down 58.6% YTD, company unprofitable with $-51.0M net loss

Du Ying, who was Chairperson & CEO at the time of filing, executed 2 separate sales totaling 100,000 shares for $1,986,875.00 on May 15 and May 18, 2026 under a pre-arranged 10b5-1 trading plan adopted on 2025-11-11, reducing holdings by 8.2% to 1,122,626 shares. The sales occurred as ZLAB's stock trades at $18.37, down 58.6% from its 52-week high of $44.34, with 30-day and 90-day declines of 24.1% and 9.0% respectively, while the company reported negative net income of $-51,016,000.00 against quarterly revenue of $99,611,000.00. His prior 5 sales at ZLAB (March 2026) all showed positive 30-day and 90-day returns, contrasting with the steep post-transaction decline now underway. The scheduled-plan nature of this filing precludes timing characterization, but the backdrop of significant stock deterioration and persistent unprofitability warrants investor attention to the company's fundamental trajectory and capital allocation.

ZLAB CEO Du Ying sells 100,000 shares for $2.0M via scheduled 10b5-1 plan; stock down -11.4% in 30 days, -53.6% from 52-week high.

Du Ying executed 5 separate sales totaling 100,000 shares for $2,003,044.43 on 2026-05-13 and 2026-05-14 under a pre-arranged 10b5-1 trading plan adopted on 2025-11-11, reducing her holdings from 1.22M shares to 1.12M shares. The transaction is scheduled and non-discretionary; pricing varied significantly across tranches (from $1.74 to $20.22 per share), reflecting market conditions during the execution window. The company is unprofitable (net income $-51,016,000.00), though revenue stands at $99,611,000.00 with annual growth of +15.3%. At current price of $20.59, the stock trades -53.6% from its 52-week high of $44.34 and is down -11.4% over the prior 30 days, a sharp decline from where some of these shares were sold.

ZLAB director Gaynor Richard buys 1,731 shares at $18.91 as stock down 56.8% from 52-week high

Director Richard Gaynor purchased 1,731 shares at $18.91 on 2026-03-17, expanding his holdings from 54,899 to 56,630 shares. The transaction occurred at a significant discount to the 52-week high of $43.03, with the stock currently trading -56.8% from its peak and down 7.1% over the preceding 30 days. Zai Lab continues to operate at a loss with net income of $-35,963,000.00 against revenue of $116,095,000.00 in the latest quarter, though the company has demonstrated +15.3% annual revenue growth. This insider purchase by a director warrants monitoring to understand whether it reflects confidence in the business trajectory or simply opportunistic accumulation at depressed valuation levels.

ZLAB CEO Du Ying sold 100,000 shares for $1,922,400.00 in 2 transactions; stock down 54.8% from 52-week high.

Du Ying, the Chairperson & CEO, executed 2 separate sales totaling 100,000 shares for $1,922,400.00 on 2026-03-06 and 2026-03-09, reducing holdings from 1,064,161 to 964,161 shares. The blended average price of $19.22 reflects modest transaction prices relative to ZLAB's 52-week range of $16.30–$43.03; the current price of $19.46 sits 54.8% below the 52-week high. At the same-ticker level, Du Ying's prior 2 measurable sales (August 2025) both registered negative 90-day returns (-38.0% and -36.1%), demonstrating well-timed execution ahead of declines. The company carries negative net income of $-35,963,000.00 on quarterly revenue of $116,095,000.00, operating at a loss despite 15.3% annual revenue growth. The consecutive sales within 3 days warrant observation of broader intent given the unprofitable operational profile.

Du Ying, then-CEO of Zai Lab, sold 100,000 shares for $1.9M under pre-arranged 10b5-1 plan

Du Ying, who held the title Chairperson & CEO at the time, executed 3 separate sales totaling 100,000 shares for $1,919,208.40 at prices ranging from $18.78 to $19.32 on 2026-03-04 and 2026-03-05. This transaction was executed under a pre-arranged 10b5-1 trading plan adopted on 2025-11-11, meaning the timing and quantities were scheduled in advance rather than discretionary. The sale reduced his holdings from 1,064,161 shares to 964,161 shares, a reduction of 100,000 shares. As a scheduled transaction under a trading plan, the filing reflects adherence to a predetermined schedule rather than a discretionary decision responsive to current market conditions.

Smiley Joshua L bought 10,000 shares of Zai Lab (ZLAB) at $28.91 on 2025-09-10; stock down 7.9% in 30 days, 0 of 4 prior buys well-timed at 90-day mark

Smiley Joshua L purchased 10,000 shares at $28.91, increasing his holdings by 13.1% to 86,604 shares total. The company's fundamentals show revenue of $109,977,000.00 for the latest quarter with annual growth of +49.6%, but it remains unprofitable with net income of $-40,727,000.00 (latest quarter) and negative full-year earnings. Relative to price context, the current price of $32.80 is 23.8% below the 52-week high of $43.03 and the stock is down 7.9% over the past 30 days. His prior buy timing at this ticker shows a concerning pattern: across 4 prior ZLAB purchases, 0 were well-timed at the 90-day mark, with cumulative 90-day performance including -24.0%, -12.7%, -32.6%, and -28.0%. The cross-ticker track record reinforces this pattern—an average 90-day return of -24.3% with a 0% win rate across 4 prior buys. This transaction represents continued accumulation into a stock where his own historical entry points have not materialized into gains within three months, and the company continues to run an operating loss despite revenue momentum.

ZLAB CEO Du Ying sells 96,387 shares for $3,357,841.59; cross-ticker track record shows well-timed sells (52.94% rate) but same-ticker history shows poor 90d outcomes.

Du Ying executed 2 separate sales totaling 96,387 shares for $3,357,841.59 on August 12–13, 2025, reducing holdings by 15.2% from 633,349 shares to 536,962 shares post-transaction. The blended average price of $34.84 falls near the current price of $34.93, suggesting limited post-sale appreciation. Across all tickers, Du Ying's prior 20 open-market sells achieved a 52.94% well-timed rate with a 90-day average return of 4.2%—indicating a modest pattern of selling ahead of weakness. However, at this specific ticker (ZLAB), his 2 prior sells with measurable 90-day outcomes both posted gains (19.0% and 22.2%), the inverse of well-timed sales; the most recent measurable same-ticker sale on 2025-06-26 returned only 2.9% at 30 days. The company remains unprofitable (net income $-40.7M on revenue of $110.0M), though it posted strong 49.6% annual revenue growth. The timing context here is mixed: cross-ticker track record suggests competence in sell-timing, but same-ticker history at ZLAB shows the opposite pattern.

Du Ying sold 100,000 shares ($3.5M) via scheduled 10b5-1 plan; post-sale holdings: 537.0K shares

Du Ying, who was Chairperson & CEO at the time of this filing, executed 2 separate sales totaling 100,000 shares for $3,468,970.00 on August 8 and 11, 2025, at a blended average price of $34.69. This transaction was part of a pre-arranged 10b5-1 trading plan adopted on 2024-11-20, meaning the sales were scheduled and non-discretionary rather than responsive to current market conditions. The sale reduced his holdings by 15.7%, from 637.0K shares to 537.0K shares. As a scheduled disposition under a pre-existing plan, this transaction does not convey timing-based signals about his contemporaneous views on valuation.

ZLAB CEO Du Ying sold 23,669 shares at $36.13 on 2025-06-26; stock down 19.3% from 52-week high.

Du Ying's sale of 23,669 shares (23.7K shares) at $36.13 represents a 4.4% reduction in holdings at a price 19.3% below the 52-week high of $43.03. The timing is noteworthy: his prior 5 trades at ZLAB (all in May 2025) occurred near the peak, with subsequent 30-day gains of +40.6% to +50.7%, suggesting strong positioning before the recent decline. His cross-ticker track record shows 19 prior sells with a 90-day well-timed rate of 100.00%, though outcomes at ZLAB are not yet measurable at the 90-day horizon. The company is unprofitable (net income $-48.4M in the latest quarter) with strong revenue growth of +49.6% year-over-year, creating a pattern consistent with early-stage biotech selling strength into execution risk.